Clone REAL282 is an antibody fragment derived from the full CD209 (DC-SIGN) antibody molecule. It displays no binding to Fc receptors. The recombinantly engineered antibody fragments are multimerized to form the REAlease Complex to bind markers with high avidity.
Clone REAL282 recognizes the CD209 antigen, also known as dendritic cell specific ICAM-3 grabbing non-integrin (DC-SIGN), a type II c-type lectin expressed in dermal and mucous tissue, lymphoid tissue such as tonsil, lymph node, spleen, as well as on monocyte-derived DCs (MoDCs). It is not expressed on DC subsets in peripheral blood, except for a subpopulation of CD14+ cells with a DC-like phenotype. DC-SIGN acts as an adhesion receptor to facilitate interactions between DCs and T cells or DCs and endothelial cells. In addition, it serves as an antigen receptor mediating internalization of ligands for antigen presentation, binding virus such as HIV, HCMV, or Ebola as well as parasites, bacteria, or yeast. HIV-1 uses this feature of DC-SIGN for efficient intrans infection of CD4+ T cells.
The REAlease Kits consist of the respective fluorochrome-conjugated REAlease Complexes and the REAlease Support Kit for removal of the REAlease Complexes and optional relabeling with different fluorochrome-conjugated REAlease Complexes.
DC-SIGN, DC-type lectin domain family 4 member L, Dendritic cell-specific ICAM-3-grabbing non-integrin 1, DC-SIGN1
Technical specifications
